A randomized, double-blind, placebo controlled, proof of concept study assessing the efficacy and safety of the RIPK1-inhibitor SAR443122 in patients with moderate to severe subacute or discoid/chronic cutaneous lupus erythematosus - Trial 2020-004703-14
Access comprehensive clinical trial information for 2020-004703-14 through Pure Global AI's free database. This phase not specified trial is sponsored by Sanofi-Aventis Recherche & Développement and is currently Completed. The study focuses on Cutaneous Lupus Erythematosus.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Free Database
Powered by Pure Global AI
840K+ Trials
2020-004703-14
Completed
Trial Details
EU Clinical Trials Register • 2020-004703-14
A randomized, double-blind, placebo controlled, proof of concept study assessing the efficacy and safety of the RIPK1-inhibitor SAR443122 in patients with moderate to severe subacute or discoid/chronic cutaneous lupus erythematosus
Study Focus
Sponsor & Location
Sanofi-Aventis Recherche & Développement
Timeline & Enrollment
N/A
N/A
N/A
Primary Outcome
Participants are excluded from the study if any of the following criteria apply:
ICD-10 Classifications
Subacute cutaneous lupus erythematosus
Lupus erythematosus
Discoid lupus erythematosus
Systemic lupus erythematosus
Systemic lupus erythematosus, unspecified
Data Source
EU Clinical Trials Register
2020-004703-14
Non-Device Trial